Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations (OTCQB:AIMLF) closed the second and final tranche of a non-brokered private placement of convertible debentures, raising an aggregate principal of $2,867,500. The new tranche totals $1,917,500.
Debentures convert at $0.05 per unit, carry 10% interest, mature on May 11, 2029, and include 36‑month warrants at $0.15. Final CSE approval is pending.
AI/ML Innovations (OTCQB:AIMLF) appointed Dr. Martin Stephen Green, a 45-year authority in electrocardiography and founding architect of Canadian cardiac electrophysiology, to its Medical Advisory Board effective April 27, 2026.
His expertise supports AIML's AI-driven ECG platform across clinical validation, regulation, and commercial deployment in major Canadian cardiac centres.
AI/ML Innovations (OTCQB:AIMLF, CSE:AIML) completed a share-for-debt issuance on April 24, 2026, issuing 17,118,420 common shares at a deemed price of Cdn$0.05 per share for total consideration of Cdn$855,921 to settle past services and outstanding indebtedness. Insiders acquired 11,848,000 Subject Shares, triggering a related party designation under MI 61-101, though the company relied on exemptions to avoid formal valuation and minority approval. The Subject Shares carry a statutory hold expiring August 25, 2026. The securities are not registered for sale in the United States.
AI/ML Innovations (OTCQB:AIMLF) completed a previously announced share-for-debt issuance on April 17, 2026, issuing 17,118,420 common shares at a deemed price of C$0.05 per share to settle past services and outstanding indebtedness.
Insiders acquired 11,848,000 of the Subject Shares, triggering a related‑party designation under MI 61-101; the company relied on specified exemptions and the Subject Shares carry a statutory hold until August 18, 2026.
AI/ML Innovations (OTCQB:AIMLF) said its subsidiary Neural Cloud signed a reseller agreement on March 25, 2026 with a European digital cardiac monitoring platform to integrate and resell MaxYield™ ECG signal‑processing technology.
The collaboration aims to expand device‑agnostic, cloud‑based remote ECG and HRV analytics for clinicians, enabling cleaner waveform data for downstream diagnostics and preventive cardiology applications.
AI/ML Innovations (OTCQB:AIMLF) closed the first tranche of a non-brokered private placement to issue $950,000 of convertible debentures on March 27, 2026.
Debentures convert to Units at $0.05 per Unit; each Unit includes one common share and one warrant exercisable at $0.15 for 36 months. Debentures bear 10% annual interest, mature March 27, 2029, and securities are subject to a statutory hold until July 28, 2026. Use of proceeds: general working capital. Offering subject to CSE final approval.
NeuralCloud (AIMLF) entered a research services agreement dated March 18, 2026 with the Baker Heart and Diabetes Institute to apply its MaxYield™ ECG processing platform to existing ECG recordings for a study of heart rate variability in post-exertional malaise.
The service converts PDF ECG traces to EDF, isolates waveform components, and generates beat-level data for HRV analysis; results are expected to support publication within the coming year. Services are non-diagnostic.
AI/ML Innovations (CSE:AIML | OTCQB:AIMLF) announced a proposed non-brokered private placement of convertible debentures of up to $3,000,000. Debentures convert into Units at $0.05 per Unit (one share + one warrant), bear 10% annual interest, and mature in 3 years.
Each Warrant is exercisable at $0.15 for 36 months from issuance. Accrued unpaid interest may convert into Units on the same terms. The Offering is subject to closing conditions and Canadian Securities Exchange approval; securities will not be offered in the United States.
AIML (OTCQB:AIMLF) said its subsidiary Neural Cloud entered a distribution agreement with Chile-based Intelimed on Feb 18, 2026 to commercialize MaxYield™, CardioYield™, and Insight360™ across Latin America. Intelimed is exclusive in Chile and non-exclusive elsewhere, targeting hospitals, clinics, OEMs, telemedicine providers and research institutions.
The partnership aims to expand access to AI-driven cardiac software, leveraging Intelimed's regional engagements and platform that aggregates FDA- and CE-authorized diagnostic tools.
AI/ML Innovations (OTCQB:AIMLF) subsidiary NeuralCloud signed a non-binding agreement with Movesense on February 11, 2026 to pilot AI-powered 1-lead ECG and Holter reporting in a third-party health system and affiliated clinics. The pilot will deploy NeuralCloud's MaxYield™ and CardioYield™ platforms alongside Movesense wearable hardware for operational validation and potential commercial rollout.
The collaboration focuses on increasing ECG screening reach, standardizing reporting, and scaling ambulatory monitoring capacity without materially increasing clinical workload; future commercialization depends on pilot results, definitive agreements, and regulatory considerations.